Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

被引：6

作者：

Inada, Kento ^{[1
]}

Kaneko, Shun ^{[1
]}

Kurosaki, Masayuki ^{[1
]}

Yamashita, Koji ^{[1
]}

Kirino, Sakura ^{[1
]}

Osawa, Leona ^{[1
]}

Hayakawa, Yuka ^{[1
]}

Sekiguchi, Shuhei ^{[1
]}

Higuchi, Mayu ^{[1
]}

Takaura, Kenta ^{[1
]}

Maeyashiki, Chiaki ^{[1
]}

Tamaki, Nobuharu ^{[1
]}

Yasui, Yutaka ^{[1
]}

Itakura, Jun ^{[1
]}

Takahashi, Yuka ^{[1
]}

Tsuchiya, Kaoru ^{[1
]}

Nakanishi, Hiroyuki ^{[1
]}

Okamoto, Ryuichi ^{[2
]}

Izumi, Namiki ^{[1
]}

机构：

[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan

[2] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

来源：

JGH OPEN | 2021年 / 5卷 / 09期

关键词：

de novo hepatitis; hepatitis B virus reactivation; tenofovir alafenamide; CYTOTOXIC CHEMOTHERAPY; DISOPROXIL FUMARATE; MANAGEMENT; INFECTION; THERAPY;

D O I：

10.1002/jgh3.12636

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aim: Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods: Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results: At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (-2.83 +/- 1.45log IU/mL vs -3.05 +/- 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (-0.62 +/- 11.2 mL/min/1.73 m(2) vs -3.67 +/- 13.2 mL/min/1.73 m(2); P = 0.291). Conclusion: TAF is safe and effective against HBV reactivation.

引用

页码：1085 / 1091

页数：7

共 28 条

[1] 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Agarwal, Kosh
Brunetto, Maurizia
Seto, Wai Kay
Lim, Young-Suk
Fung, Scott
Marcellin, Patrick
Ahn, Sang Hoon
Izumi, Namiki
Chuang, Wan-Long
Bae, Ho
Sharma, Manoj
Janssen, Harry L. A.
Pan, Calvin Q.
Celen, Mustafa Kemal
Furusyo, Norihiro
Shalimar, Dr
Yoon, Ki Tae
Huy Trinh
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Cathcart, Andrea L.
Lin, Lanjia
Bhardwaj, Neeru
Suri, Vithika
Subramanian, G. Mani
Gane, Edward J.
Buti, Maria
Chan, Henry L. Y.
[J]. JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 672 - 681
[2] JS']JSH Guidelines for the Management of Hepatitis B Virus Infection
Asahina, Yasuhiro
Hayashi, Norio
Hiramatsu, Naoki
Izumi, Namiki
Koike, Kazuhiko
Kumada, Hiromitsu
Kurosaki, Masayuki
Oketani, Makoto
Suzuki, Fumitaka
Takikawa, Hajime
Tanaka, Atsushi
Tanaka, Eiji
Tanaka, Yasuhito
Tsubouchi, Hirohito
Yotsuyanagi, Hiroshi
[J]. HEPATOLOGY RESEARCH, 2014, 44 : 1 - 58
[3] Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
Buti, Maria
Manzano, Maria L.
Morillas, Rosa M.
Garcia-Retortillo, Montserrat
Martin, Leticia
Prieto, Martin
Gutierrez, Maria L.
Suarez, Emilio
Gomez Rubio, Mariano
Lopez, Javier
Castillo, Pilar
Rodriguez, Manuel
Zozaya, Jose M.
Simon, Miguel A.
Morano, Luis E.
Calleja, Jose L.
Yebenes, Maria
Esteban, Rafael
[J]. PLOS ONE, 2017, 12 (09):
[4] Buti M, 2016, LANCET GASTROENTEROL, V1, P90, DOI [10.1016/S2468-1253(16)30107-8, 10.1016/S2468-1253(16)30020-6]
[5] Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Chan, Henry L. Y.
Fung, Scott
Seto, Wai Kay
Chuang, Wan-Long
Chen, Chi-Yi
Kim, Hyungjoon
Hui, Aric Josun
Janssen, Harry L. A.
Chowdhury, Abhijit
Tsang, Tak Yin Owen
Mehta, Rajiv
Gane, Edward
Flaherty, John F.
Massetto, Benedetta
Gaggar, Anuj
Kitrinos, Kathryn M.
Lin, Lanjia
Subramanian, G. Mani
McHutchison, John G.
Lim, Young-Suk
Acharya, Subrat K.
Agarwal, Kosh
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03): : 185 - 195
[6] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico P.
Agarwal K.
Berg T.
Buti M.
Janssen H.L.A.
Papatheodoridis G.
Zoulim F.
Tacke F.
[J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
[7] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Mulla, Sohail
Wang, Yulei
Lim, Ho Yeong
Zhu, Andrew X.
Cheng, Ann-Lii
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
[8] REACTIVATION OF CHRONIC HEPATITIS B-VIRUS INFECTION BY CANCER-CHEMOTHERAPY
HOOFNAGLE, JH
DUSHEIKO, GM
SCHAFER, DF
JONES, EA
MICETICH, KC
YOUNG, RC
COSTA, J
[J]. ANNALS OF INTERNAL MEDICINE, 1982, 96 (04) : 447 - 449
[9] Huang H, 2014, JAMA-J AM MED ASSOC, V312, P2521, DOI 10.1001/jama.2014.15704
[10] Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update
Hwang, Jessica P.
Feld, Jordan J.
Hammond, Sarah P.
Wang, Su H.
Alston-Johnson, Devena E.
Cryer, Donna R.
Hershman, Dawn L.
Loehrer, Andrew P.
Sabichi, Anita L.
Symington, Banu E.
Terrault, Norah
Wong, Melisa L.
Somerfield, Mark R.
Artz, Andrew S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3698 - +

← 1 2 3 →